Prof. Dr. H.J. (Henk-Jan) Guchelaar

Vakgebied(en)

  • Ziekenhuisapotheker-Klinisch Farmacoloog
  • Hoogleraar Klinische Farmacie
  • Afdelingshoofd Klinische Farmacie en Toxicologie

Introductie

In 1989 rondde ik de opleiding farmacie af en promoveerde in 1993 aan de Rijksuniversiteit Groningen (RuG). In de jaren daarna specialiseerde ik me tot ziekenhuisapotheker en klinisch farmacoloog. Ik ben in verschillende ziekenhuizen werkzaam geweest als productieapotheker, laboratoriumapotheker en als hoofd apotheek en opleider. Sinds 2003 ben ik ziekenhuisapotheker / klinisch farmacoloog en hoogleraar Klinische Farmacie en hoofd van de afdeling Klinische Farmacie & Toxicologie van het Leids Universitair Medisch Centrum. Vanaf oktober 2008 ben ik tevens hoogleraar Klinische Farmacie bij de faculteit Wiskunde en Natuurwetenschappen aan de Leidse Universiteit waar ik trekker ben van het profileringsgebied Translational Drug Discovery and Development van de Leidse Universiteit. Farmaceutische patiëntenzorg en oncologie vormen mijn belangrijkste klinische aandachtsgebieden.


Research Focus

The main topic of my research is pharmacogenetics. It is my ambition to optimize drug treatment for patients, and in particular cancer or rheumatoid arthritis patients. More effective and safer drug therapy is achieved by individualization and by use of genetic biomarkers. Therefore, we focus on the discovery of genetic biomarkers that are related to individual drug response. In addition, we aim to develop algorithms that include genetic and non-genetic markers that can be readily translated to daily clinical practice. 

To achieve these research ambitions we have formed a group of experts that covers the required fields within the field of clinical pharmacology, pharmacogenomics, pharmacokinetics, pharmacodynamics, pharmacometrics and bio-analytics within the department of Clinical Pharmacology & Toxicology. This combination of expertise allows the successful identification of genetic biomarkers for drug response while the clinical environment enables prompt translation to patient care. For the optimization of drug therapy for the individual patient (i.e. personalised medicine) additional expertise, all available in Leiden, are required. For this reason we have recently set-up the Leiden Network for Personalised Therapeutics (LNPT) . In addition, we strongly collaborate with partners in the USA, Asia and Europe. An example is the Ubiquitous Pharmacogenomics (U-PGx) project (H2020-PHC-2015) which is coordinated by our department. The aim of this project is to make actionable pharmacogenomic data and effective treatment optimization accessible to every European citizen.


Key Publications

van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, Dávila-Fajardo CL, Deneer VH, Dolžan V, Ingelman-Sundberg M, Jönsson S, Karlsson MO, Kriek M, Mitropoulou C, Patrinos GP, Pirmohamed M, Samwald M, Schaeffeler E, Schwab M, Steinberger D, Stingl J, Sunder-Plassmann G, Toffoli G, Turner RM, van Rhenen MH, Swen JJ, Guchelaar HJ; Ubiquitous Pharmacogenomics Consortium. Implementing Pharmacogenomics in Europe: Design and Implementation Strategy of the Ubiquitous Pharmacogenomics Consortium. Clin Pharmacol Ther. 2017 Mar;101(3):341-358. doi:10.1002/cpt.602.

Auffray C, Balling R, Barroso I, Bencze L, Benson M, Bergeron J, Bernal-Delgado E, Blomberg N, Bock C, Conesa A, Del Signore S, Delogne C, Devilee P, Di Meglio A, Eijkemans M, Flicek P, Graf N, Grimm V, Guchelaar HJ, Guo YK, Gut IG, Hanbury A, Hanif S, Hilgers RD, Honrado Á, Hose DR, Houwing-Duistermaat J, Hubbard T, Janacek SH, Karanikas H, Kievits T, Kohler M, Kremer A, Lanfear J, Lengauer T, Maes E, Meert T, Müller W, Nickel D, Oledzki P, Pedersen B, Petkovic  M, Pliakos K, Rattray M, I Màs JR, Schneider R, Sengstag T, Serra-Picamal X, Spek W, Vaas LA, van Batenburg O, Vandelaer M, Varnai P, Villoslada P, Vizcaíno JA, Wubbe JP, Zanetti G. Making sense of big data in health research: Towards an EU action plan. Genome Med. 2016 Jun 23;8(1):71. doi: 10.1186/s13073-016-0323-y. Erratum in: Genome Med. 2016 Nov 7;8(1):118.

Lunenburg CA, Henricks LM, Guchelaar HJ, Swen JJ, Deenen MJ, Schellens JH, Gelderblom H. Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time. Eur J Cancer. 2016 Feb;54:40-8. doi: 10.1016/j.ejca.2015.11.008.

Diekstra MH, Swen JJ, Boven E, Castellano D, Gelderblom H, Mathijssen RH, Rodríguez-Antona C, García-Donas J, Rini BI, Guchelaar HJ. CYP3A5 and ABCB1 polymorphisms as predictors for sunitinib outcome in metastatic renal cell carcinoma. Eur Urol. 2015 Oct;68(4):621-9. doi: 10.1016/j.eururo.2015.04.018.

Coenen MJ, de Jong DJ, van Marrewijk CJ, Derijks LJ, Vermeulen SH, Wong DR, Klungel OH, Verbeek AL, Hooymans PM, Peters WH, te Morsche RH, Newman WG, Scheffer H, Guchelaar HJ, Franke B; TOPIC Recruitment Team. Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease. Gastroenterology. 2015 Oct;149(4):907-17.e7. doi: 10.1053/j.gastro.2015.06.002.

Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, Kochi Y, Ohmura K, Suzuki A, Yoshida S, Graham RR, Manoharan A, Ortmann W, Bhangale T, Denny JC, Carroll RJ, Eyler AE, Greenberg JD, Kremer JM, Pappas DA, Jiang L, Yin J, Ye L, Su DF, Yang J, Xie G, Keystone E, Westra HJ, Esko T, Metspalu A, Zhou X, Gupta N, Mirel D, Stahl EA, Diogo D, Cui J, Liao K, Guo MH, Myouzen K, Kawaguchi T, Coenen MJ, van  Riel PL, van de Laar MA, Guchelaar HJ, Huizinga TW, Dieudé P, Mariette X, Bridges SL Jr, Zhernakova A, Toes RE, Tak PP, Miceli-Richard C, Bang SY, Lee HS, Martin J, Gonzalez-Gay MA, Rodriguez-Rodriguez L, Rantapää-Dahlqvist S, Arlestig L, Choi HK, Kamatani Y, Galan P, Lathrop M; RACI consortium.; GARNET consortium., Eyre S, Bowes J, Barton A, de Vries N, Moreland LW, Criswell LA, Karlson EW, Taniguchi A, Yamada R, Kubo M, Liu JS, Bae SC, Worthington J, Padyukov L, Klareskog L, Gregersen PK, Raychaudhuri S, Stranger BE, De Jager PL, Franke L, Visscher PM, Brown MA, Yamanaka H, Mimori T, Takahashi A, Xu H, Behrens TW, Siminovitch KA, Momohara S, Matsuda F, Yamamoto K, Plenge RM. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014 Feb 20;506(7488):376-81.  doi: 10.1038/nature12873.

Cui J, Stahl EA, Saevarsdottir S, Miceli C, Diogo D, Trynka G, Raj T, Mirkov MU, Canhao H, Ikari K, Terao C, Okada Y, Wedrén S, Askling J, Yamanaka H, Momohara S, Taniguchi A, Ohmura K, Matsuda F, Mimori T, Gupta N, Kuchroo M, Morgan AW, Isaacs JD, Wilson AG, Hyrich KL, Herenius M, Doorenspleet ME, Tak PP,  Crusius JB, van der Horst-Bruinsma IE, Wolbink GJ, van Riel PL, van de Laar M, Guchelaar HJ, Shadick NA, Allaart CF, Huizinga TW, Toes RE, Kimberly RP, Bridges  SL Jr, Criswell LA, Moreland LW, Fonseca JE, de Vries N, Stranger BE, De Jager PL, Raychaudhuri S, Weinblatt ME, Gregersen PK, Mariette X, Barton A, Padyukov L, Coenen MJ, Karlson EW, Plenge RM. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet. 2013 Mar;9(3):e1003394. doi: 10.1371/journal.pgen.1003394.
 


Contactgegevens

Leids Universitair Medisch Centrum
Gebouw 1
Kamer L-00-171

Albinusdreef 2
2333 ZA Leiden
Tel: 071 526 4018

Postzone L0-P
Postbus 9600
2300 RC Leiden

E-mail: h.j.guchelaar@lumc.nl